CN111789845A - Application of GYKI11679 compound in cytokine release syndrome of CAR-T therapy - Google Patents

Application of GYKI11679 compound in cytokine release syndrome of CAR-T therapy Download PDF

Info

Publication number
CN111789845A
CN111789845A CN201910277548.3A CN201910277548A CN111789845A CN 111789845 A CN111789845 A CN 111789845A CN 201910277548 A CN201910277548 A CN 201910277548A CN 111789845 A CN111789845 A CN 111789845A
Authority
CN
China
Prior art keywords
cells
gyki11679
chimeric antigen
cancer
antigen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910277548.3A
Other languages
Chinese (zh)
Inventor
刘茂玄
许晨光
温丽联
曾滢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Bindebio Technology Co ltd
Original Assignee
Shenzhen Bindebio Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Bindebio Technology Co ltd filed Critical Shenzhen Bindebio Technology Co ltd
Priority to CN201910277548.3A priority Critical patent/CN111789845A/en
Publication of CN111789845A publication Critical patent/CN111789845A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention provides application of GYKI11679 compounds in preparation of a preparation for preventing and/or treating cytokine release syndrome caused by CAR-T therapy. Also provided is a pharmaceutical composition for treating malignant tumor, autoimmune disease or AIDS, comprising chimeric antigen receptor T cells and GYKI11679 compounds. According to the invention, the chimeric antigen receptor T cell and the GYKI11679 compound are combined, so that CRS side effects caused by CAR-T cell therapy can be prevented and/or treated at a low economic cost, and a good treatment effect of the CAR-T cell therapy is further exerted.

Description

Application of GYKI11679 compound in cytokine release syndrome of CAR-T therapy
Technical Field
The invention relates to the technical field of medicines, in particular to application of GYKI11679 compounds in cytokine release syndrome of CAR-T therapy.
Background
Malignant diseases such as cancer are diseases which seriously harm human health in the global scope and seriously affect life. Currently, the treatment methods for cancer and the like include nonspecific immunotherapy, active immunotherapy, adoptive cellular immunotherapy, and the like. Among them, adoptive cellular immunotherapy is considered as a method in which it is possible to completely eliminate cancer cells in the existing technologies. The chimeric antigen receptor T cell (CAR-T) technology, one of the latest immune cell technologies in current adoptive cell-based therapeutic technologies, is to transfuse genetically modified T lymphocytes (which can express specific chimeric antigen receptors) back into the human body, and activate the T lymphocytes in a manner independent of major histocompatibility complexes, thereby specifically killing malignant target cells such as cancer cells. The CAR-T technology has strong targeting, killing activity and persistence on malignant cells, thereby showing great application prospect in the aspect of treating malignant diseases such as cancer and the like.
Although CAR-T cell therapy has achieved good results in some clinical trials, it has also been associated with serious side effects, such as the most common Cytokine Release Syndrome (CRS) at present, resulting in significant increases in the levels of certain cytokines in the patient's blood, fever, tachycardia, hypotension, etc., and, in severe cases, multiple organ failure and death. Therefore, there is a need to inhibit cytokine release during CAR-T cell immunotherapy and alleviate/eliminate CRS side effects to improve the therapeutic efficacy of CAR-T cells.
Disclosure of Invention
In view of the above, the present invention provides a technical solution for preventing or treating CRS caused by CAR-T cell immunotherapy.
In a first aspect, the invention provides the use of a compound of the GYKI11679 class in the preparation of a medicament for the prevention and/or treatment of Cytokine Release Syndrome (CRS) caused by chimeric antigen receptor T (CAR-T) cell therapy.
Wherein, the GYKI11679 compounds comprise GYKI11679, tautomers thereof, pharmaceutically acceptable salts thereof or prodrugs thereof and GYKI11679 derivatives.
Wherein, the structural formula of GYKI11679 is shown as the following formula (I):
Figure BDA0002020541040000021
wherein the CAR-T cell therapy comprises use in the treatment of a malignancy, an autoimmune disease or AIDS.
Further, the malignant tumor includes one or more of leukemia, lymphoma, multiple myeloma, brain glioma, liver cancer, lung cancer, stomach cancer, esophageal cancer, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, cervical cancer and prostate cancer, but is not limited thereto.
Further, the autoimmune disease includes one or more of systemic lupus erythematosus, rheumatoid arthritis, chronic active hepatitis, scleroderma, pemphigus, dermatomyositis, ulcerative colitis, and hashimoto's thyroiditis, but is not limited thereto.
The GYKI11679 compound is a micromolecular drug, the price of the GYKI11679 compound is much lower than that of an antibody drug for inhibiting cell factors after CRS side effect occurs, and the aim of reducing CRS side effect caused by CAR-T cell therapy can be achieved at lower economic cost; meanwhile, GYKI11679 can inhibit the activity of various cytokines by inhibiting the release of catecholamines, compared with the antibody drug which can only inhibit the activity of one cytokine, so that the CRS can be prevented and/or treated better.
In a second aspect, the invention also provides a pharmaceutical composition comprising a chimeric antigen receptor T (CAR-T) cell and a GYKI 11679-like compound.
Optionally, the CAR-T cells comprise CAR-T cells that target one or more of CD19, CD20, CD22, CD33, CD38, CD317, BCMA, EGFR, Mesothelin, DR5, c-met, OX40, HER 2.
Wherein the T cells in the CAR-T cells are from autologous T cells, allogeneic T cells, or iPSC-induced T cells.
In the pharmaceutical composition, the CAR-T cell and the GYKI11679 compound can be present independently or in a mixture. When used as a pharmaceutical combination, the two may be administered simultaneously, sequentially or in different modes of administration.
In one embodiment of the invention, the CAR-T cells are administered intravenously and the GYKI 11679-based compound is administered intraperitoneally.
In a third aspect, the invention also provides an application of the pharmaceutical composition in preparing a preparation for treating malignant tumor, autoimmune disease or AIDS.
According to the invention, the CAR-T cell and the GYKI11679 compound are combined, so that CRS side effects (not only inhibiting the level of a cytokine) caused by CAR-T cell therapy can be prevented and/or treated, and a better treatment effect of the CAR-T cell therapy is further exerted.
Detailed Description
While the following is a description of the preferred embodiments of the present invention, it will be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention.
The embodiment of the invention provides application of GYKI11679 compounds in preparing a preparation for preventing and/or treating Cytokine Release Syndrome (CRS) caused by chimeric antigen receptor T (CAR-T) cell therapy.
Wherein, the structural formula of GYKI11679 is shown as the following formula (I):
Figure BDA0002020541040000031
the "GYKI 11679-like compound" of the present invention may include, in addition to GYKI11679, its tautomer, or its pharmaceutically acceptable salt or prodrug, and various derivatives that can be modified by simple chemical methods (such as reduction, substitution, etc.) on its skeleton by those skilled in the art, and still remain for preventing and/or treating CRS caused by CAR-T cell therapy, and the synthesis methods of these derivatives can be referred to textbooks in the prior art.
Wherein, "pharmaceutically acceptable salt" refers to a salt of a compound prepared from a pharmaceutically acceptable non-toxic acid (including inorganic acids, organic acids), non-toxic base (including inorganic bases, organic bases), solvate, hydrate or clathrate. The "prodrugs" may be prepared in situ during isolation and purification of the compounds, or by separately reacting the purified compounds with suitable derivatizing agents.
The research of the applicant of the invention finds that the GYKI11679 compound can prevent and/or treat CRS caused by CAR-T cell therapy by inhibiting the release of fine factors.
The GYKI11679 compound is a micromolecular drug, the price of the GYKI11679 compound is much lower than that of an antibody drug for inhibiting cell factors after CRS side effect occurs, and the aim of reducing CRS side effect caused by CAR-T cell therapy can be achieved at lower economic cost; meanwhile, GYKI11679 can inhibit the activity of various cytokines by inhibiting the release of catecholamines, compared with the antibody drug which can only inhibit the activity of one cytokine, so that the CRS can be prevented and/or treated better.
CAR-T cells of the invention include CAR-T cells that target a variety of different malignant disease targets, such as: targeting one or more of CD19, CD20, CD22, CD33, CD38, CD317, BCMA, EGFR, Mesothelin, DR5, c-met, OX40, HER2, and the like.
Wherein the T cells in the CAR-T cells are from autologous T cells, allogeneic T cells, or iPSC-induced T cells.
Wherein the CAR-T cell therapy comprises use in the treatment of a malignancy, an autoimmune disease or AIDS.
Further, the malignant tumor includes one or more of leukemia, lymphoma, multiple myeloma, brain glioma, liver cancer, lung cancer, stomach cancer, esophageal cancer, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, cervical cancer and prostate cancer, but is not limited thereto.
Further, the autoimmune disease includes one or more of systemic lupus erythematosus, rheumatoid arthritis, chronic active hepatitis, scleroderma, pemphigus, dermatomyositis, ulcerative colitis, and hashimoto's thyroiditis, but is not limited thereto.
Embodiments of the invention also provide a pharmaceutical composition comprising a chimeric antigen receptor T (CAR-T) cell and a GYKI 11679-like compound. The pharmaceutical composition is used for treating malignant tumor, autoimmune disease or AIDS, and can also be used for preventing and/or treating Cytokine Release Syndrome (CRS) caused by chimeric antigen receptor T (CAR-T) cell therapy.
Optionally, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is preferably chemically inert to the GYKI 11679-type compounds of the invention and does not have deleterious side effects or toxicity under the conditions of use.
Such pharmaceutically acceptable carriers, e.g., excipients, stabilizers, suspending agents or diluents, and the like, are well known to those skilled in the art and are publicly available. Exemplary carriers can include water, physiological saline, aqueous dextrose and related sugar solutions, monohydric alcohols (such as ethanol, isopropanol or cetyl alcohol), glycols (such as propylene glycol or polyethylene glycol), glycerol, ketals (such as 2, 2-dimethyl-1, 3-dioxolane-4-methanol), ethers (such as poly (ethylene glycol) 400), oils, fatty acids, fatty acid esters or glycerides, acetylated fatty acid glycerides with or without pharmaceutically acceptable surfactants, such as soaps or detergents, suspending agents (such as pectin, carbomer, methyl cellulose, hydroxypropyl methyl cellulose or carboxymethyl cellulose), or emulsifying agents and other pharmaceutical adjuvants. The choice of the carrier will depend in part on the particular GYKI11679 class of compound selected, as well as the particular method used to administer the composition.
In the pharmaceutical composition, the CAR-T cell and the GYKI11679 compound can be present independently or in a mixture. When used as a pharmaceutical combination, the two may be administered simultaneously, sequentially or in different modes of administration.
For example, the CAR-T cells are administered parenterally, e.g., intravenously, intraarterially, subcutaneously, intradermally, intrathecally, or intramuscularly. The CAR-T cells can be dissolved or suspended in a solution suitable for parenteral administration in an acceptable carrier, including isotonic sterile injectable aqueous and non-aqueous solutions. The GYKI11679 compounds can be administered orally, intravenously, subcutaneously, intramuscularly, intraperitoneally, sublingually, or by spraying to the nasal cavity. When the GYKI11679 compound is administered by intravenous injection, subcutaneous injection, intramuscular injection, etc., it can be prepared into injection preparation.
In one embodiment of the invention, the CAR-T cells are administered intravenously and the GYKI 11679-based compound is administered intraperitoneally.
Where the GYKI 11679-like compound is used in conjunction with CAR-T cells, various concentrations of the GYKI 11679-like compound may be used in conjunction with various concentrations (or amounts) of CAR-T cells. For example, the CAR-T cells used have a density of 0.5X 106～5×106Individual cells/mL. For example, 1X 106、2×106Or 0.5X 106Individual cells/mL.
In addition, the embodiment of the present invention also provides a method for treating malignant tumor, autoimmune disease or AIDS, which comprises administering the pharmaceutical composition of the present invention to a test subject with malignant target cells.
The concentration of the GYKI 11679-like compound, the concentration (or number) of CAR-T cells may be adjusted depending on the particular test subject. Wherein the malignant target cell is a cell targeted by the CAR-T cell. Such as cells corresponding to the above-mentioned malignant tumor, autoimmune disease or AIDS.
Optionally, the CAR-T cell to malignant target cell number ratio is (2-10): 1. for example 2.5:1, 5:1 or 10: 1.
The treatment of CRS resulting from CAR-T cell immunotherapy in the treatment of tumors using GYKI 11679-based compounds is described below as a specific example. The reagents used in the present invention are all common commercial products, and are all commercially available.
The method comprises the following specific steps:
1. mixing newborn (0-2 days) SGM3(NSG Tg)CMV-IL3,CSF2,KITLG1Eav/MloySzJ) mice were irradiated with sublethal doses (150cGy) and immediately injected intrahepatically with 1X 105Individual human cord blood CD34+ cells, a nhsgm 3 humanized mouse was prepared. Humanized mouse T cells of nhsgm 3 were used to generate CAR-T cells targeted to CD 19.
2. Adult (6-8 weeks) SGM3(NSG Tg)CMV-IL3,CSF2,KITLG1Eav/MloySzJ) mice were irradiated with a sublethal dose (200 cGy) and injected immediately via tail vein with 1X 105Individual human cord blood CD34+ cells, HuSGM3 humanized adult mice were prepared.
After 3.4 weeks, the adult mice in step 2 were injected 2X 10 by tail vein injection6CD 19-targeted CAR-T cells prepared from nHuSGM3 humanized mice in step 1.
4. Immediately after CAR-T cell injection, GYKI 1167910 mg/kg or an equal volume of PBS was i.p. daily for 3 consecutive days.
5. Weighing the body weight of the mice each day after the injection of the CAR-T cells, and measuring the body temperature of the mice; blood was taken every two days and the serum levels of human IL-6, IL-10, TNF- α and mouse serum amyloid A were measured. The CRS-related indexes are continuously detected for 21 days.
As a result, compared with the CAR-T cell therapy only targeting CD19 on the adult mouse with the tumor, the CAR-T cell therapy targeting CD19 and the hydrochloride of GYKI11679 on the adult mouse with the tumor have the advantages of low body temperature and low content of cytokines such as human IL-6, IL-10 and TNF-alpha in serum. This suggests that the use of GYKI 11679-like compounds has significant therapeutic effects on CRS caused by CAR-T cell immunotherapy in tumor treatment.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.

Claims (10)

  1. The application of the GYKI11679 compound in preparing a preparation for preventing and/or treating cytokine release syndrome caused by chimeric antigen receptor T cell therapy.
  2. 2. The use according to claim 1, wherein the GYKI 11679-like compound comprises GYKI11679, tautomers thereof, pharmaceutically acceptable salts thereof or prodrugs thereof, and GYKI11679 derivatives.
  3. 3. The use of claim 1, wherein said chimeric antigen receptor T cell therapy comprises treatment of a malignancy, an autoimmune disease, or aids.
  4. 4. The use of claim 3, wherein the malignancy comprises one or more of leukemia, lymphoma, multiple myeloma, brain glioma, liver cancer, lung cancer, stomach cancer, esophageal cancer, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, cervical cancer and prostate cancer;
    the autoimmune disease comprises one or more of systemic lupus erythematosus, rheumatoid arthritis, chronic active hepatitis, scleroderma, pemphigus, dermatomyositis, ulcerative colitis, and hashimoto's thyroiditis.
  5. 5. A pharmaceutical composition comprising a chimeric antigen receptor T cell and a GYKI 11679-type compound.
  6. 6. The pharmaceutical composition of claim 5, wherein the chimeric antigen receptor T cell is a chimeric antigen receptor T cell that targets one or more of CD19, CD20, CD22, CD33, CD38, CD317, BCMA, EGFR, Mesothelin, DR5, c-met, OX40, HER 2.
  7. 7. The pharmaceutical composition of claim 5, wherein the T cells used in the chimeric antigen receptor T cells are derived from autologous T cells, allogeneic T cells, or iPSC-induced T cells.
  8. 8. The pharmaceutical composition of any one of claims 5-7, wherein the chimeric antigen receptor T cells and the GYKI11679 compound are present alone or in admixture; the administration mode of the chimeric antigen receptor T cells and the GYKI11679 compound comprises simultaneous administration, sequential administration or administration in different administration modes.
  9. 9. The pharmaceutical composition of claim 8, wherein the chimeric antigen receptor T cells are administered intravenously and the GYKI11679 compound is administered intraperitoneally.
  10. 10. Use of a pharmaceutical composition according to any one of claims 5-9 for the preparation of a formulation for the treatment of malignant tumors, autoimmune diseases or aids.
CN201910277548.3A 2019-04-08 2019-04-08 Application of GYKI11679 compound in cytokine release syndrome of CAR-T therapy Pending CN111789845A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910277548.3A CN111789845A (en) 2019-04-08 2019-04-08 Application of GYKI11679 compound in cytokine release syndrome of CAR-T therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910277548.3A CN111789845A (en) 2019-04-08 2019-04-08 Application of GYKI11679 compound in cytokine release syndrome of CAR-T therapy

Publications (1)

Publication Number Publication Date
CN111789845A true CN111789845A (en) 2020-10-20

Family

ID=72805687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910277548.3A Pending CN111789845A (en) 2019-04-08 2019-04-08 Application of GYKI11679 compound in cytokine release syndrome of CAR-T therapy

Country Status (1)

Country Link
CN (1) CN111789845A (en)

Similar Documents

Publication Publication Date Title
CN108348492B (en) Methods for cancer and immunotherapy using glutamine analogs
US10821127B2 (en) Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient
US20230310419A1 (en) Compounds and methods for treating cancer
WO2014142220A1 (en) Anti-tumor agent
US20170340628A1 (en) Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
KR20200123137A (en) Method of using trisubstituted benzotriazole derivatives
CN112807434A (en) Application of PERK inhibitor in preparation of synergist of liver cancer drug
CN114516857A (en) HPK1 inhibitors and uses thereof
US8569280B2 (en) Methods for the treatment of multiple myeloma
US20070003558A1 (en) Methods for the treatment of multiple myeloma
WO2020207257A1 (en) Application of artemisinin compounds in promoting chimeric antigen receptor t cell treatment, and pharmaceutical composition
CN111789845A (en) Application of GYKI11679 compound in cytokine release syndrome of CAR-T therapy
CN111789834A (en) Application of small octreone compounds in preventing and treating cytokine release syndrome caused by CAR-T therapy
CN109528731B (en) Pharmaceutical composition with synergistic effect for treating multiple myeloma and application thereof
CN111789829A (en) Application of U-5021 compounds in preventing and treating cytokine release syndrome caused by CAR-T therapy
CN111789836A (en) Application of Pyratrione compound in cytokine release syndrome of CAR-T therapy
CN111789841A (en) Application of anopheline compound in preventing and treating cytokine release syndrome caused by CAR-T therapy
Furuhata et al. Histamine-releasing properties of T-3762, a novel fluoroquinolone antimicrobial agent in intravenous use. I. Effects of doses and infusion rate on blood pressure, heart rate and plasma histamine concentration
US20230405132A1 (en) Antitumor pharmaceutical composition and use thereof
EP1881835A1 (en) Triazine compounds and compositions thereof for the treatment of cancers
KR20210039414A (en) Combination therapy for the treatment of cancer
CN106166291B (en) Medical application of spleen polypeptide in improving KLRK1 or LCK treatment immunosuppression
CN112770760A (en) Methods and compositions for reducing radiation-induced toxicity
US10702534B2 (en) Compositions and methods relating to the radioprotective effects of apilimod
WO2023160112A1 (en) Azaphilone compound and use thereof in preparation of anti-tumor drugs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201020